Claims: STAT+: How Trump’s latest pharma deals may undermine efforts to rein in drug costs
These are attributed source records, not independent verification of each assertion.
Complete claim record (JSON) · Original source
- title: STAT+: How Trump’s latest pharma deals may undermine efforts to rein in drug costs Source
- url: https://www.statnews.com/2026/09/02/trump-most-favored-nation-drug-pricing-industry-analysts-skeptical/?utm_campaign=rss Source
- summary: WASHINGTON — The White House announced more drug pricing deals on Monday, this time with midsize biotechnology companies. In doing so, President Trump once again grabbed headlines on a topic he believes will benefit Republicans in the midterm elections. But the voluntary deals might not amount to much, at least not immediately, according to analysts. That’s because they chiefly apply to Medicaid , which by law gets the lowest prices of any U.S. payer, while exempting companies from mandatory pri… Source
- published: Wed, 02 Sep 2026 08:30:00 +0000 Source